9 Meters Biopharma, Inc. has ceased operations. The Company has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	14 12.69 11.73 10.59 19.95 1.32K 20.66 140.96 55.9 705.14 52.54 51.42 2.24K	P/E 2021	-6.47x	P/E 2022	-0.37x
Enterprise Value	7.08M 6.42M 5.94M 5.36M 10.09M 668M 10.45M 71.32M 28.28M 357M 26.58M 26.02M 1.13B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

23-11-28	Bidding Procedure Approved for 9 Meters Biopharma, Inc.	CI
23-11-26	Amendment to Motion for Asset Sale Filed by 9 Meters Biopharma, Inc.	CI
23-11-06	Motion for Asset Sale Filed by 9 Meters Biopharma, Inc.	CI
23-11-02	Motion for Asset Sale Filed by 9 Meters Biopharma, Inc.	CI
23-08-09	Illumina cuts annual profit forecast as biotech funding woes linger	RE
23-08-09	Illumina cuts annual profit forecast	RE
23-07-25	Danaher cuts forecast for annual sales growth as biotech clients face funding crunch	RE
23-07-25	9 Meters Biopharma, Inc.(OTCPK:NMTR.Q) dropped from NASDAQ Composite Index	CI
23-07-21	9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from S&P TMI Index	CI
23-07-18	Drug developer 9 Meters Biopharma files for bankruptcy protection	RE
23-07-17	9 Meters Biopharma, Inc. Filed for Bankruptcy	CI
23-05-30	9 Meters Biopharma Names Bethany Sensenig Interim Chief Executive; Shares Fall	MT
23-05-30	9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome	CI

23-05-18	Citigroup Adjusts 9 Meters Biopharma Price Target to $0.75 From $1.70, Maintains Neutral Rating	MT
23-03-20	Truist Downgrades 9 Meters Biopharma to Hold From Buy	MT
23-02-13	Citigroup Initiates Coverage on 9 Meters Biopharma With Neutral Rating, $2.70 Price Target	MT
22-11-02	Oppenheimer Adjusts 9 Meters Biopharma Price Target to $51 From $5, Maintains Outperform Rating	MT
22-09-27	Oppenheimer Adjusts Price Target on 9 Meters Biopharma to $5 From $4, Maintains Outperform Rating	MT

23-10-02	Celiac Disease Pipeline, Clinical Trials, FDA Approvals, and Emerging Drugs 2023 (Updated)	AQ
23-05-30	9 METERS BIOPHARMA, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23-05-22	9 METERS BIOPHARMA, INC. : Other Events (form 8-K)	AQ
23-04-27	9 METERS BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Financial Statements and Exhibits (form 8-K)	AQ
23-04-06	9 METERS BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INNOVATE BIOPHARMACEUTICALS INC	+2.14%	-0.75%	-	-	1.44K
INVESTOR AB	+0.09%	+1.76%	+33.67%	+108.89%	132B
INDUSTRIVÄRDEN AB	-1.00%	+2.26%	+33.81%	+84.51%	23.24B
HAL TRUST	+0.57%	+3.54%	+27.62%	+59.06%	17.5B
LUNDBERG B	-0.08%	+0.75%	+18.29%	+31.57%	14.98B
INVESTMENT AB LATOUR	+0.95%	-0.81%	-0.56%	+12.91%	14.78B
MERITZ FINANCIAL GROUP INC.	+5.42%	-10.21%	-2.14%	+119.00%	14.29B
BAJAJ HOLDINGS & INVESTMENT LIMITED	-1.52%	+0.42%	-11.62%	+55.78%	13.1B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	-1.15%	+1.64%	+32.05%	+41.03%	12.42B
KINGDOM HOLDING COMPANY	-6.43%	+4.03%	+60.33%	+81.23%	12.49B
Average	-0.10%	+0.66%	+21.27%	+66.00%	28B
Weighted average by Cap.	-0.10%	+1.23%	+27.26%	+86.28%

Innovate Biopharmaceuticals Inc Stock Nasdaq

Stocks

US61174L5012

Investment Holding Companies

Valuation: Innovate Biopharmaceuticals Inc

Latest news: Innovate Biopharmaceuticals Inc

Analysts' recommendations: Innovate Biopharmaceuticals Inc

Press Releases: Innovate Biopharmaceuticals Inc

Quotes and Performance

Shell Companies

Financials

Company Profile

	2021	2022
Net sales	-	-
Net income	-36.78M -33.33M -30.83M -27.81M -52.42M -3.47B -54.26M -370M -147M -1.85B -138M -135M -5.88B	-43.77M -39.66M -36.68M -33.1M -62.37M -4.13B -64.57M -441M -175M -2.2B -164M -161M -7B
Net Debt	-46.83M -42.43M -39.25M -35.41M -66.73M -4.42B -69.09M -471M -187M -2.36B -176M -172M -7.49B	7.08M 6.42M 5.94M 5.36M 10.09M 668M 10.45M 71.32M 28.28M 357M 26.58M 26.02M 1.13B